MX2015012200A - Composiciones de oxaliplatino en liposomas para la terapia contra el cancer. - Google Patents

Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.

Info

Publication number
MX2015012200A
MX2015012200A MX2015012200A MX2015012200A MX2015012200A MX 2015012200 A MX2015012200 A MX 2015012200A MX 2015012200 A MX2015012200 A MX 2015012200A MX 2015012200 A MX2015012200 A MX 2015012200A MX 2015012200 A MX2015012200 A MX 2015012200A
Authority
MX
Mexico
Prior art keywords
oxaliplatin
cancer therapy
mol
lipid
compositions
Prior art date
Application number
MX2015012200A
Other languages
English (en)
Inventor
William Mcghee
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of MX2015012200A publication Critical patent/MX2015012200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invención proporciona una composición para el tratamiento del cáncer, que incluye liposomas zwitteriónicos que consisten esencialmente de: 50-70% en mol de. un lípido de fosfatidilcolina, 25-45% en mol de colesterol y 2- 8% en mol de un lípido-PEG; y oxaliplatino. El oxaliplatino se encapsula en los liposomas en una cantidad tal que la relación del peso total de lípidos con respecto al peso de oxaliplatino es de aproximadamente 20:1 a aproximadamente 65:1. También se dan a conocer métodos para la preparación de oxaliplatino liposomal y el tratamiento del cáncer.
MX2015012200A 2013-03-13 2014-03-12 Composiciones de oxaliplatino en liposomas para la terapia contra el cancer. MX2015012200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780000P 2013-03-13 2013-03-13
PCT/US2014/025029 WO2014159760A1 (en) 2013-03-13 2014-03-12 Liposome oxaliplatin compositions for cancer therapy

Publications (1)

Publication Number Publication Date
MX2015012200A true MX2015012200A (es) 2015-11-30

Family

ID=50686128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012200A MX2015012200A (es) 2013-03-13 2014-03-12 Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.

Country Status (8)

Country Link
US (1) US20140271820A1 (es)
EP (1) EP2968144A1 (es)
JP (2) JP6341987B2 (es)
CN (1) CN105451720A (es)
BR (1) BR112015022476A2 (es)
CA (1) CA2903234C (es)
MX (1) MX2015012200A (es)
WO (1) WO2014159760A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131006A1 (en) * 2015-02-13 2016-08-18 Orient Pharma Inc. Compositions and methods of tumor treatment utilizing nanoparticles
AU2016352874B2 (en) * 2015-11-10 2021-06-24 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
WO2017192502A1 (en) * 2016-05-03 2017-11-09 The American University In Cairo Liposomal delivery systems for oxaliplatin and in dual drug delivery in combination with chemo-sensitizing and chemo-therapeutic agents
US11246832B2 (en) * 2016-06-28 2022-02-15 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
CN106474057A (zh) * 2016-12-02 2017-03-08 中国药科大学 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法
WO2018106980A1 (en) * 2016-12-08 2018-06-14 Mallinckrodt Llc Liposomal elinafide formulations and uses thereof
WO2018149358A1 (zh) 2017-02-17 2018-08-23 科济生物医药（上海）有限公司 靶向il-13ra2的抗体及其应用
US20210113464A1 (en) * 2017-11-27 2021-04-22 Osaka University Disease-site-specific liposomal formulation
US20230165795A1 (en) * 2018-03-20 2023-06-01 Universiteit Twente Liposomes for targeting tumor-associated macrophages
JP7235870B2 (ja) * 2018-09-14 2023-03-08 アンセルム（アンスティチュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 薬物送達システム
WO2020159171A2 (ko) * 2019-02-01 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
CN110101848A (zh) * 2019-04-11 2019-08-09 天津大学 一种逆转肿瘤细胞顺铂耐药纳米药物及其制备方法和应用
CN110507613A (zh) * 2019-07-29 2019-11-29 苏州大学 一种脂质体制剂及其制备方法与应用
WO2021072407A1 (en) * 2019-10-10 2021-04-15 The University Of North Carolina At Chapel Hill Delivery system complexes comprising a precipitate of an active agent and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1369132A (en) * 1919-03-29 1921-02-22 Ane P Schat Adjustable inclined davit
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
JP2006041422A (ja) * 2004-07-30 2006-02-09 Seiko Epson Corp 半導体基板、半導体装置、半導体基板の製造方法および半導体装置の製造方法
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
JP5769701B2 (ja) * 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 脂質組成物
ES2733061T3 (es) * 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Dispersión acuosa de liposomas encapsulantes de oxaliplatino estable y método para estabilización de la misma

Also Published As

Publication number Publication date
WO2014159760A1 (en) 2014-10-02
EP2968144A1 (en) 2016-01-20
JP6341987B2 (ja) 2018-06-13
US20140271820A1 (en) 2014-09-18
CN105451720A (zh) 2016-03-30
JP2016512550A (ja) 2016-04-28
BR112015022476A2 (pt) 2017-07-18
CA2903234C (en) 2018-08-28
JP2018119015A (ja) 2018-08-02
CA2903234A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
MX2015012200A (es) Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.
MX2015012199A (es) Composiciones de cisplatino liposomal para la terapia contra el cancer.
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
IN2014DN05866A (es)
MX2019003334A (es) Composiciones liposomicas de inhibidores de proteasoma basadas en epoxicetona.
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
NZ732777A (en) Ionizable cationic lipid for rna delivery
TR201816986T4 (tr) Terapötik ajan iletim formülasyonlarına yönelik lipitler.
WO2008070463A3 (en) Endoxifen methods and compositions
EA200801912A1 (ru) Лечение рака
NZ718817A (en) Lipid formulations for delivery of messenger rna
WO2012153338A3 (en) Liposomes comprising polymer-conjugated lipids and related uses
SG10201906075VA (en) Methods of treating cancer
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
WO2013170012A3 (en) Proliposomal testosterone formulations
GR1008018B (el) Λιπιδικα συμπλοκα αποτελουμενα απο ανιονικα λυσο-λιπιδια και η εφαρμογη αυτων
MX2012012914A (es) Proceso para elaborar composiciones liquidas suavizantes de telas.
PH12015501239A1 (en) Oral care products comprising tetrabasic zinc chloride and trimethylglycine
WO2015033302A3 (en) Fulvestrant compositions
MX2016002302A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
IN2014MN01571A (es)
WO2012119781A3 (en) Novel lipids, phospholipids, phospholipid and lipid compositions and their use
MX2016009217A (es) Inmunoterapia basada en liposomas.